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Background: Studies reported here were conducted to evaluate the safety and effectiveness of advantus™
(imidacloprid) soft chewable tablets for the treatment of flea (Ctenocephalides felis) infestations on dogs and
puppies 10 weeks of age or older and weighing 4 pounds or greater.
Methods: A pharmacokinetic study was conducted to evaluate parameters of orally administered imidacloprid. A
dose confirmation study was conducted to confirm the efficacy of 0.75 mg/kg at 8, 12 or 24 hours post-treatment.
A knockdown and speed of kill study was conducted to confirm the efficacy of 0.75 mg/kg dose at 0.5, 1, 4 or
24 hours post-treatment. The safety of a daily dose administered for six months at approximately 1, 3, and 5 times
the maximum exposure dose of 3.75 mg/kg was evaluated in puppies. A field study was conducted to evaluate the
safety and efficacy of a daily oral dose of 0.75 mg/kg for 14 days in client-owned dogs.
Results: The pharmacokinetic parameters of the final imidacloprid oral formulation were; Tmax 1.31 hours, Cmax
690.0 ng/mL, AUC 2615.5 h*ng/mL and half-life was 2.2 hours.
The efficacy of 0.75 mg/kg BW was 98.6 %, 99.9 % and 100 % at 8, 12 and 24 hours post-treatment, respectively.
The live flea counts were significantly different (p < 0.0001) and the treatment was well tolerated.
The flea counts at 1 hour post-treatment were significantly lower in the treated group and the speed of kill efficacy
was 96.6 % at 4 hours post-treatment in the knockdown and speed of kill study.
The target animal safety study showed that the advantus™ soft chewable tablets administered orally to 10-week-old
puppies once daily for 6 months at approximately 1, 3 and 5 times the maximum dose of 3.75 mg/kg was well
tolerated and did not produce clinically relevant findings in Beagles.
In the field study, efficacy of the soft chewable tablets administered daily for 14 days to flea-infested dogs was
98.2 %.
Conclusion: Imidacloprid administered orally as a soft chewable tablet for the treatment of fleas on dogs was safe
and highly effective with a rapid knockdown effect and rapid elimination.
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The cat flea, Ctenocephalides felis, is the most important
parasite found on dogs worldwide [1]. Flea infestations
result in itching, anemia in heavy infestations, and flea
allergy dermatitis (FAD). Fleas are also competent vec-
tors of several pathogens, including bartonellosis, rick-
ettsial infections [2, 3] and Dipylidium caninum [4].
Significant advancements have been made within the
past 20 years for the control of flea infestations of dogs
and cats. Control methods have evolved from treating
the pet and its indoor and outdoor environment to only
treating the pet [5] because active ingredients have been
developed that have rapid activity, persistent activity,
and in some cases broad spectrum of activity. In
addition to being highly efficacious, various delivery sys-
tems have also been developed to provide convenience
of application including sprays, topical spot-on, collars
and systemic products, such as injectable or oral formu-
lations. These advancements have made it possible to ef-
fectively control flea infestations on pets at a very high
level.
Imidacloprid is a neo-nicotinoid insecticide introduced
in the USA in 1996 as a veterinary and agricultural prod-
uct [6]. Imidacloprid is a competitive inhibitor of the
nicotinic acetylcholine receptors of target insects in
postsynaptic nerves which prevents acetylcholine from
binding and transmitting information resulting in inco-
ordination, loss of motor skills and death of the insect
[7, 8]. The compound is effective against insects because
they have a large proportion of nicotinic acetylcholine
receptors and because imidacloprid has a higher binding
affinity to insect nerve receptors than to mammalian re-
ceptors [9]. As with other neo-nicotinoids, imidacloprid
has selective activity against fleas and other insect spe-
cies with less activity against acarines [10].
In animal health, imidacloprid was first developed as
a topical insecticide (Advantage®) with excellent efficacy
for treatment and control of fleas on dogs and cats. Sin-
gle spot-on application of imidacloprid at 7.5 and
10.0 mg/kg killed fleas on dogs within 24 hours and
had effective residual activity for 34 days [6]. The effi-
cacy was not affected by shampooing or exposing the
dog to water [11, 12]. Combining imidacloprid with
other products extended the spectrum of activity. Imi-
dacloprid was combined with permethrin (K9 Advan-
tix®, Advantix®) to extend activity against ticks [13, 14]
and add repellent activity against sand flies on dogs
[15]. The combination of imidacloprid and moxidectin
(Advantage Multi®, Advocate®) is used for prevention of
heartworm disease [16] and for treatment of fleas, in-
testinal nematodes [17], sarcoptic mange [18], demodex
mange [19] and ear mites [20]. Imidacloprid combined
with pyriproxyfen (Advantage II®) extended the activity
against all life stages of fleas [21].This manuscript describes five studies conducted for
the development of advantus™ soft chewable tablets con-
taining imidacloprid for treatment of flea infestations on
dogs and puppies 10 weeks of age or older and weighing
4 lb (1.8 kg) or greater. The advantus™ soft chewable
tablets are available in two sizes; 7.5 mg imidacloprid for
dogs weighing 4 to 22 lb (1.8–10 kg) in weight and
37.5 mg imidacloprid for dogs weighing 23 to 110 lb
(10–50 kg) in weight. Studies were conducted to estab-
lish the pharmacokinetic characteristics, for substantial
evidence of activity against fleas (efficacy and speed of
kill), for confirmation of safety in target species, and to
evaluate field experience regarding safety and efficacy of
the product as used by pet owners.Methods
Ethical approval
All laboratory protocols were approved by the Institu-
tional Animal Care and Use Committees at each facility.
Animal husbandry and housing were in compliance with
Animal Welfare Act Regulations. All owners who en-
rolled their dogs in the field study signed an Owner’s
Consent form.
With the exception of the pharmacokinetic study, the
studies reported here were conducted under Good Clin-
ical Practice (GCP) and Good Laboratory Practice (GLP)
standards in compliance with VICH GL9 guidelines June
2000, and 21CFR Part 511. The studies were designed in
accordance with standard methods for evaluating effi-
cacy of parasiticides for treatment of flea infestations
[22] and as well as safety [23].
The protocols for the laboratory studies specified the
use of purebred beagles or mixed-breed dogs that had
not been treated with an acaricide, insecticide, or an in-
sect growth regulator for the previous 60 days. All la-
boratory study dogs originated from test facility colony
or were purchased from commercial sources and were
acclimated to the test facility environment for 7 to
10 days prior to study initiation. Dogs were individually
housed in indoor pens or cages that conformed to the
national standards for area, size, lighting, and
temperature. Water was available ad libitum and an ad-
equate amount of commercial dog food was provided
for daily maintenance.
During the acclimation period the dogs were bathed
with a non-medicated shampoo and combed to remove
any pre-existing fleas. Health observations were con-
ducted daily during the conduct of studies. Pre-
treatment physical examinations of all dogs were con-
ducted. For the efficacy studies, a pre-treatment flea in-
festation followed 24 hours later with a flea comb count
was conducted to determined susceptibility of the dogs
to flea infestations. Pre-treatment flea counts were used
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into study groups as defined by the protocol.
Fleas used for the laboratory efficacy studies were ei-
ther purchased commercially or were reared at the site
insectary as per site Standard Operating Procedures
(SOPs). Vials containing approximately 100 recently
emerged adult fleas were prepared for each dog for each
designated infestation by vacuum system transfer. Each
dog was infested by placing the fleas from each vial on
the dorsal midline area and restraining the dog for a suf-
ficient time to allow the fleas to move into the hair and
establish infestation.
Fleas were counted using a fine toothed flea comb to
recover fleas present in the animal’s fur. The combing
procedure was as described in the site SOPs and con-
formed to industry standards. The total numbers of live
and dead fleas collected were recorded on the data
forms. Removed fleas showing no movements were con-
sidered dead.
The geometric mean numbers of live adult fleas on
dogs in the control groups were compared to the geo-
metric mean number of live adult fleas on treated dogs
at each time point. Percent effectiveness was calculated
using Abbott’s formula as follows:
Efficacy %ð Þ ¼ 100 X Mc – Mtð Þ=Mc
Mc = Geometric mean of live fleas in the control
group
Mt = Geometric mean of live fleas in the treatment
group
All analyses were performed using SAS/STAT® soft-
ware (Version 9, SAS System for Windows, Copyright©
2002–2003 by SAS Institute Inc., Cary, NC, USA). An
analysis of variance (ANOVA, SAS PROC MIXED) using
log (live flea count +1) transformations compared the
live flea counts of treatment group and the control at
each time point. The comparisons were tested using the
(two-sided) 5 % significance level. The fixed model ana-
lysis was used to analyze log-counts, with treatment
group as a fixed effect.
Pharmacokinetics
A pharmacokinetic study was conducted to determine
the rate and extent of absorption of imidacloprid admin-
istered to eight dogs as a soft chewable tablet. The dogs
were fasted overnight prior to dosing. Each dog was
dosed orally with the final formulation of the soft chew-
able tablet containing 7.5 mg imidacloprid. Approxi-
mately 4 mL of blood was collected from each dog at
pre-dose and at 0.25, 0.5, 1, 2, 4, 8 and 12 hours post-
treatment. Serum was collected in 0.5 ml aliquot, frozen
and sent to an analytical laboratory (En-CAS Analytical
Laboratories, Winston-Salem, NC) for analysis using avalidated analytical method. The limit of quantitation
(LOQ) was 1.0 ppb.
Pharmacokinetic analysis was accomplished using
WinNonLin (version 5.3, PharSight Corp., Inc. Moun-
tain View, CA) to estimate individual pharmacokinetic
parameters. Descriptive statistics (number of observa-
tions, means, standard deviations and minimum and
maximum values) were determined for Tmax, Cmax and
AUC last.
Dose confirmation
A GCP study was conducted to confirm the effectiveness
of advantus™ soft chewable tablets (Investigational Veter-
inary Product (IVP)) administered at the minimum dose
of 0.75 mg/kg body weight for the treatment of adult flea
infestations on dogs.
Fifty-six dogs were acclimated at the test facility for
9 days prior to the study initiation and processed as pre-
viously described. Forty-eight dogs with the highest flea
counts were selected for the study and randomized to
one of three study groups of 16 dogs each for flea counts
conducted at 8, 12 or 24 hours post-treatment. Within
each study group, dogs were randomly assigned to one
of two treatments groups; the advantus™ treated (IVP)
group and the placebo treated (Control Veterinary Prod-
uct, CVP) control group for a total of 8 dogs per treat-
ment group. On Day −1, the body weight of each dog
was measured for dose calculation and then all dogs
were infested with approximately 100 recently emerged
unfed adult fleas. The dogs were fasted overnight prior
to dosing on Day 0. Dogs were randomly assigned to
treatment order and treated on Day 0 with 7.5 mg imi-
dacloprid IVP or placebo CVP soft chewable tablets, de-
pending on their assigned treatment group. Comb
counts were performed at 8, 12 and 24 hours post-
treatment, respectively. General health observations
were conducted daily from the start of acclimation
through to the end of the study. Additional health obser-
vations for treatment related adverse reactions were con-
ducted pre-treatment, and at 1, 2 and 4 hours post-
treatment.
The geometric mean of live fleas (defined as alive or
moribund) on dogs in the control groups were com-
pared to the geometric mean of live fleas on treated dogs
at each time point. Percent effectiveness was calculated
and the transformed live flea count data was compared
to determine the difference between the treated and the
control groups at each time point.
Knockdown and speed of kill
A GCP study was conducted to determine the speed of
kill of the IVP administered orally at a minimum dose of
0.75 mg/kg body weight for the treatment of adult cat
flea (C. felis) infestations of dogs.
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10 days. Forty-eight healthy dogs with the highest flea
counts and meeting all other protocol requirements
were enrolled in the study. The dogs were randomly
assigned to two treatment groups either the sham
treated control group (non-treated) or the IVP treated
group. The two groups were randomized further to a
combing time of 0.5, 1, 4 or 24 hours post-treatment
.All dogs were weighed on Day −3 for accurate dosing.
On Day −1, all dogs were infested with approximately
100 adult fleas. The dogs were fasted overnight prior to
dosing on Day 0. All dogs were randomized to treatment
order and those dogs assigned to the treated group were
dosed with the IVP based on the dog’s body weight.
Dogs weighing 4.0–22.0 lb (1.8–10 kg) received the
7.5 mg tablet and those dogs weighing more than > 22.1 lb
(10 kg) received the 37.5 mg tablet. Dogs assigned to
the control group were sham treated to maintain mask-
ing and to establish a time for post-treatment activities.
After treatment on Day 0, dogs from treated and con-
trol groups were combed to determine the total live flea
counts at the assigned time and analyzed as stated
earlier.
Target animal safety
The purpose of this GLP study was to assess the safety
of the advantus™ soft chewable tablets when adminis-
tered orally to Beagle puppies, starting at approximately
10 weeks old (±3 days), daily for six months at approxi-
mately 1, 3, and 5 times the targeted maximum exposure
of 3.75 mg/kg body weight (the highest dose within the
weight band).
Three treatment groups of four male and four female
Beagle dogs were administered the advantus™ soft chew-
able tablets at the respective dose level of approximately
1, 3, or 5 times the daily dose once a day for 182 con-
secutive days. One additional group of eight (four ani-
mals/sex) served as the control and was sham dosed
once a day for 182 consecutive days.
Observations for morbidity, mortality, injury and
availability of food and water were conducted twice
daily for all animals. Clinical observations were con-
ducted twice per day, at least six hours apart (once in
the AM and once in the PM). Body weights were mea-
sured and recorded three times per week during the ac-
climation period, three times during Week 1, twice
during Week 2 and weekly thereafter. Dry and wet food
consumption were measured, recorded daily and re-
ported weekly during the dosing period. The individual
daily food consumption was also reported. Ophthalmo-
scopic examinations were conducted pre-test and prior
to the terminal necropsy. Physical and neurologic ex-
aminations were conducted pre-test, weekly for the first
4 weeks, and monthly thereafter. Blood and urinesamples for clinical pathology evaluations were col-
lected from all animals on Day −4 and at 1, 3, 4.5, and
6 months. Fecal samples were collected on Day −4 and
at 1, 3, 4.5, and 6 months and were observed for color
and consistency. Fecal samples were collected and dir-
ect and indirect ova and parasite evaluations were per-
formed on all animals on Days −12 and −4. Blood
samples for thyroid hormone (T4) evaluations were col-
lected on Day −4 and at 1, 3, 4.5, and 6 months. At
study termination, necropsy examinations were per-
formed, organ weights were recorded, and tissues were
microscopically examined.
The continuous endpoints measured during the
study were analyzed by a repeated measures analysis of
covariance with treatment, sex, day, treatment-by-sex,
treatment-by-day, sex-by-day and treatment-sex-day
terms in the model as fixed effects. Baseline measure-
ments were included as covariates. Continuous end-
points measured once were analyzed by analysis of
variance. All statistical comparisons of main effects
and two-way interactions were performed at the 0.10
level of significance. The three-way interactions were
performed at the 0.05 level of significance. Follow-up
pairwise mean comparisons between the zero dose
group and each non-zero dose group were performed,
as necessary, using linear contrasts with significance
level of 0.10.
Field safety and efficacy
The objective of this GCP study in client owned dogs
was to evaluate the field safety and effectiveness of daily
oral treatment administered for 14 consecutive days, for
the treatment of flea infestations on dogs. The study de-
sign was a masked placebo controlled multi-center field
study conducted at various veterinary clinics. The indi-
vidual household was the experimental unit and each
household was randomly assigned to one of two treat-
ment groups: daily oral IVP or placebo control (CVP).
The numbers of cases enrolled in each group were in a
ratio of 2:1. All personnel at each clinic were masked to
the treatment groups except the person responsible for
assigning the household to the treatment group. This
person did not participate in any other study related ac-
tivity. Both IVP and CVP soft chewable tablets were
available in the same size and were indistinguishable
from each other. The tablet bottles were labelled with
letter codes, which were not available to the clinic
personnel.
At each site, the investigator was the clinic veterinar-
ian who was responsible for the protocol, oversight of
owner communication, animal examinations and super-
vision of flea counts. The investigator ensured that the
owners had signed an owner’s consent, had agreed to
follow protocol requirements, and agreed to administer
Table 1 Summary of pharmacokinetic parameters in dogs









4153 1 654 3075.4 3.01
4181 1 557 1938.61 1.62
4374 1 764 2846.85 2.16
4386 0.5 693 2101.38 2.06
4140 4 512 3093.1 2.27
4175 1 812 2756.6 2.09
4182 1 777 2866.6 2.41
4383 1 751 2245.5 2.1
Mean 1.31 690 2615.5 2.2
Qureshi et al. Parasites & Vectors  (2015) 8:407 Page 5 of 10the daily treatments as described below. The owners had
also demonstrated a clear understanding of the require-
ments of study participation and agreed to comply with
study instructions, restrictions and visits.
Dogs enrolled in the study were 8 weeks of age or
older, 4 pounds or greater in body weight and were
healthy and in good condition. There were no breed or
gender restrictions. No topical, systemic or environmen-
tal flea treatment or preventative products were allowed
within the previous 30 days. Other concomitant medica-
tions that did not interfere with study results were
allowed. These included mild conditions or disease that
did not interfere with flea infestations. To qualify for in-
clusion the dog was required to have an affiliation with
the household. Dogs excluded from the study included
those receiving monthly oral or topical heartworm pre-
ventatives that also contained a flea treatment or control
medication. Households with cats were included in the
study, however all cats were treated at the clinic within
2 days of dog enrollment using any approved monthly
flea treatment and control product.
Households with one or more dogs with flea infesta-
tions were enrolled in the study. The owners brought all
the dogs to the clinic for the initial visit and a physical
examination was conducted on all the dogs. A comb
count was conducted on the dogs and the first dog,
which had 10 or more fleas, was classified as the primary
dog. All remaining dogs in the household were consid-
ered as secondary dogs. The household did not qualify
for enrollment if none of the dogs in the household had
10 or more fleas. All dogs in each household received
the same IVP or CVP treatment.
At each site, the qualifying households were assigned
to a treatment group according to a pre-assigned
randomization generated by a SAS statistical package to
either the IVP or the CVP soft chewable tablet group.
The dose tested was a minimum dose of 0.75 mg/kg
body weight available in two sizes; 7.5 mg soft chewable
tablets for dogs of 4.0 − 22.0 lb (1.8 − 10.0 kg body
weight) and 37.5 mg soft chewable tablets for dogs of
22.1 − 110.0 lb (10.0 − 50.0 kg body weight). The investi-
gator instructed the owners on the methods to adminis-
ter the oral treatments, once a day for 14 consecutive
days and document the treatments administered and any
observations in the dosing diary. The owners were
instructed to monitor the dogs for 1 hour after dosing
for vomiting, coughing, gagging, retching, drooling, sali-
vation or any other adverse events and record these ob-
servations in the dosing diary. The owners were
instructed to bring the dogs back for the final visit for
flea counts and safety assessments.
Field safety assessments were done during the initial
visit (Day 1) and the final visit (Day 14). On Day 1, phys-
ical examinations were conducted on all dogs in thehousehold, but on Day 14, it was only conducted on the
primary dog. Blood samples were collected for routine
hematology (CBC) and serum chemistry variables and
T4 analysis. Urine samples were collected for routine
urinalysis including specific gravity and pH evaluations.
The mixed model analysis included the fixed effect
of ‘Treatment’, the random effects of ‘Site’ and the
interaction of ‘Treatment and Site’ (random effect).
Hematology, serum chemistry and urinalysis were sta-
tistically evaluated via an analysis of covariance
(ANCOVA) using SAS PROC MIXED with the pre-
treatment value used as covariate. The model included
terms for the effects ‘Treatment’ and ‘Site’ as well as
the interaction ‘Treatment by Site’. The terms ‘Site’




The body weight of the dogs ranged from 19.6 to
22.9 lb (8.9 kg to 10.4 kg ; mean 21.1 lb or 9.6 kg). Imi-
dacloprid was identified in serum samples from all
treated dogs with recoveries ranging from 82 % to
114 % with a mean of 104 % ± 9.7 %. Individual results
for pharmacokinetic parameters, calculated using Win-
NonLin non-compartmental modeling for the variables
Tmax, Cmax and AUClast, are presented in Table 1 and a
graph of the average serum concentration of imidaclo-
prid (± SD) is shown in Fig. 1. The Tmax was 1.31 hours,
Cmax was 690.0 ng/mL, AUClast was 2615.5 h*ng/mL
and the half-life was 2.2 hours following oral dosing of
advantus™ soft chewable tablets.
Dose confirmation
The 48 dogs enrolled in the dose confirmation study
consisted of 34 Beagles, 1 Rat Terrier and 13 mixed
breeds. There were 22 male and 26 females, who were
Fig. 1 Serum concentration of imidacloprid following administration of advantus™ chewable tablets to dogs
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from 9 months to 7.5 years in age. All dogs were suscep-
tible to flea infestation as determined by the pre-
treatment flea counts. Pre-treatment comb counts
ranged from 75 to 100 fleas. These dogs were randomly
allocated to treatment groups.
The animals were dosed with their assigned 7.5 mg IVP
soft chewable tablet or the placebo CVP soft chewable tablet
following confirmation of the dogs’ IDs (microchip reader or
tattoos). The treatment administered ensured a minimum
dose of 0.34 mg/lb BW (0.75 mg/kg BW). The actual dose
administered to the dogs ranged from 0.34 – 0.42 mg/lb BW
(0.75 − 0.92 mg/kg BW) of imidacloprid.
Dogs were combed until fleas were no longer found.
Infestation of the three CVP groups were considered ad-
equate as more than 50 % of fleas infesting the dogsTable 2 Confirmation of 0.75 mg/kgbody weight as the dose of adv
Time1 Treatment Variable N Mean Std D
8 IVP2 Count 8 3.00 6.55
LogCount 8 0.31 0.46
CVP3 Count 8 85.13 27.37
LogCount 8 1.89 0.25
12 IVP Count 8 0.13 0.35
LogCount 8 0.04 0.11
CVP Count 8 89.75 7.32
LogCount 8 1.96 0.04
24 IVP Count 8 0.00 0.00
LogCount 8 0.00 0.00
CVP Count 8 91.13 6.62
LogCount 8 1.96 0.03
1Time in hours post-treatment when efficacy was determined
2IVP is the advantus™ chewable tablets as the investigational veterinary product
3CVP is the placebo chewable tablets as control veterinary product
4Statistically significant at p < 0.01were recovered at each combing period in more than six
dogs per group. The mean flea counts recovered from
each group and the calculated efficacy are listed in
Table 2. The mean live flea counts from the IVP treated
dogs were significantly lower than the counts from the
CVP groups at each count time (p < 0.0001). The efficacy
was 98.6 %, 99.9 % and 100 % at 8, 12 and 24 hours
post-treatment, respectively. Therefore, advantus™ soft
chewable tablets provided efficacy of >98 % at 8, 12 and
24 hours post-treatment at a minimum dose of 0.75 mg/
kg body weight.
Knockdown and speed of kill
The 48 dogs enrolled in the knockdown and speed of kill
study consisted of 41 Beagles and 7 mixed breeds. There
were 26 males and 22 females, who were 14.3 to 37.1 lbantus™ chewable tablet
ev Minimum Maximum Efficacy (%) p-value
0.00 19.00
0.00 1.30 98.63 <.00014
18.00 100.00
1.28 2.00








Qureshi et al. Parasites & Vectors  (2015) 8:407 Page 7 of 10(6.5 − 16.86 kg) in body weight and ranged from
8.2 months to 7.8 years in age. All dogs were susceptible
to flea infestation as determined by the pre-treatment
flea counts. Pre-treatment comb counts ranged from
45–100 fleas/dog. These dogs were randomly allocated
to treatment groups.
The dogs were dosed with their assigned imidacloprid
soft chewable tablet of either 7.5 or 37.5 mg. The dogs
in the control group remained non-treated; however, a
time was assigned to each dog to maintain masking and
to establish a time for post-treatment activities. The
identity of each dog was confirmed before each treat-
ment was administered. The treatment administered en-
sured a minimum dose of 0.34 mg/lb (0.75 mg/kg) and
the actual dose administered to the dogs ranged from
0.34 − 1.70 mg/lb (0.75 − 3.75 mg/kg) of imidacloprid.
No adverse events were observed in any dog during the
study.
All dogs were combed to conduct a complete body
flea comb count to recover and count all live fleas.
Dogs were combed until fleas were no longer found. In-
festation of the control groups were considered ad-
equate as more than 50 % of fleas infesting the dogs
were recovered at each combing time point. The mean
flea counts recovered from each group and the calcu-
lated efficacy are listed in Table 3. The mean live flea
counts from the treated dogs were significantly lower
than the counts from the control groups (p < 0.007) at
1, 4 and 24 hours post-treatment.Table 3 Knockdown and Speed of kill efficacy of advantus™ chewab
Time1 Treatment Variable N Mean Std D
0.5 Treated Count 6 79.00 29.37
LogCount 6 1.86 0.25
Control Count 6 94.33 4.63
LogCount 6 1.98 0.02
1 Treated Count 6 64.33 12.99
LogCount 6 1.81 0.08
Control Count 6 91.00 13.56
LogCount 6 1.96 0.07
4 Treated Count 6 3.17 1.60
LogCount 6 0.60 0.15
Control Count 6 85.83 7.22
LogCount 6 1.94 0.04
24 Treated Count 6 0.17 0.41
LogCount 6 0.05 0.12
Control Count 6 94.83 5.27
LogCount 6 1.98 0.02
1Time in hours post-treatment when efficacy was determined
2Statistically significantFlea efficacy was 24.6 %, 29.7 %, 96.6 % and 99.9 % at
0.5, 1, 4 and 24 hours post-treatment, respectively. Al-
though dead fleas were noted at 0.5 hour, the number of
live fleas recovered from the treated group and the con-
trol group was significantly different at 1 hour for the
start of kill effect. The speed of kill at 4 hours post-
treatment was > 90 %. The treatment was well tolerated
and no abnormal clinical observations were observed in
dogs when administered at a minimum dose of 0.75 mg/
kg body weight.
Target animal safety
Based on body weights and dose administered, the
daily treatments administered were 3.74 mg/kg/day,
11.22 mg/kg/day and 18.7 mg/kg/day (0.9X, 2.7X and
4.5X). No effect of treatment was observed on any
parameter evaluated including survival, physical exam-
inations, bodyweights, food consumption, clinical
pathology, clinical chemistry, urinalysis, fecal exami-
nations, thyroid hormone (T4), and necropsy or histo-
pathology examinations. The treatment was well
tolerated with no evidence of toxicity observed in any
of the parameters evaluated.
Field safety and efficacy
Sixteen veterinary clinics at different geographical loca-
tions across the United States were recruited to conduct
the study. Two hundred primary cases were enrolled of
which 118 received the IVP soft chewable tablet and 82le tablet administered at 0.75 mg/kg BW
ev Minimum Maximum Efficacy(%) p-value
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enrolled of which 88 dogs received the IVP and 43 dogs
received the CVP. Therefore, a total of 206 dogs were
treated with IVP and 125 were treated with CVP. All
treated dogs were included for safety evaluations but
only 104 treated dogs and 69 control dogs were included
for pivotal effectiveness evaluations. Several cases were
excluded from pivotal effectiveness evaluation for vari-
ous reasons including failure to complete the study, fail-
ure of the owners to return for the final visit, owners’
non-compliance with instructions, incorrect dosing or
failure of the clinic to enroll the minimum required
number of dogs.
Various breeds were enrolled in the study; the most
common was mixed breed dogs. Up to 58 different
breeds were recorded for the dogs enrolled in the study.
The age of the dogs enrolled ranged from 2 months to
15 years. A total of 167 female and 164 male dogs were
enrolled in the study. Of these dogs 109 females and 96
males were spayed or neutered. The weights of the dogs
ranged from 4–118 lb (1.8 – 54 kg) and were adminis-
tered 0.66 mg to 4.0 mg imidacloprid/kg body weight.
A total of 173 cases (104 dogs in the treated group
and 69 dogs in the control group) were included in the
pivotal effectiveness evaluation. The geometric mean live
flea counts on Day 14 were 0.4 in the treated group and
21.0 in the control group. These counts were signifi-
cantly different (p < 0.0001). The efficacy of advantus™
soft chewable tablets administered for 14 consecutive
days was 98.2 %.
A total of 331 cases (206 dogs in the treated group
and 125 dogs in the control group) were evaluated for
field safety. No serious adverse events related to the IVP
were reported during the study. Dogs in both groups
had minor adverse events and the nature and frequen-
cies of the adverse events observed are provided in
Table 4. One dog had an episode of ataxia observed only
on Day 7 and not reproduced on any other day. The dog
was admitted to the hospital for further observation and
no other clinical signs were observed.
Blood, serum, and urine samples were obtained from
the primary dogs on Days 1 and on Day 14. An analysisTable 4 Summary of adverse events observed during the advantus™
Adverse event No. of cases in the IVP1 trea
(n (%) as total of 206 dogs)
Vomiting, upset stomach 8 (3.8 %)
Inappetence 6 (2.9 %)
Lethargy 4 (1.9 %)
Diarrhea, flatulence 3 (1.5 %)
Ataxia 1 (0.5 %)
1IVP is the advantus™ chewable tablets as the investigational veterinary product
2`CVP is the placebo soft chewable tablets as control veterinary productof variance was performed on the variables to determine
the difference between the treated versus the control
groups. For the hematology analysis, although the means
of all variables were within the normal range, the vari-
ables hematocrit, hemoglobin, MCHC and RBC were
significantly higher in the treated group than the control
group. These variables indicate loss of blood and were
predicted because of the continued flea infestations on
the control group. For serum chemistry, including T4
analysis, although the means of all variables were within
the normal range, the variables that were significantly
different were albumin, AST, calcium, cholesterol and
total protein. The findings of albumin, calcium and total
protein indicate loss of blood as a result of continued
flea infestations of the control group. The difference in
cholesterol was most likely due to the varied prandial
states of the dogs at the time of serum collection, while
the AST difference could be the result of concomitant
use of corticosteroids in multiple dogs. There were no
differences in any of the urinalysis variables.
Dosing naturally infested dogs with advantus™ soft
chewable tablets for 14 consecutive days by dog owners
was 98.2 % effective for the treatment of cat flea infesta-
tions. The mean live flea count in the treated group was
significantly lower than the mean live flea count in the
control group. No serious treatment related adverse
events were observed in any dog during the study and it
was concluded that advantus™ soft chewable tablets are
safe for the treatment of flea infestation on dogs.
Discussion
Neo-nicotinoids administered orally are characterized as
products that have a rapid and complete absorption,
resulting in rapid activity and a short half-life [24]. In
this study, imidacloprid administered orally as soft chew-
able tablets demonstrated these characteristics. Imida-
cloprid was rapidly and completely absorbed with a Tmax
of approximately 1 hour and it was also rapidly elimi-
nated with a half-life of approximately 2 hours. The Cmax
was approximately 700 ng/mL indicating that high levels
were achieved within 1 hour, which would predict a
rapid speed of kill activity.soft chewable tablets field study
ted group No. of cases in the CVP2 treated group
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vidual factors of the flea biology and life cycle [25] that
are playing out in each individual pet’s environment. Ef-
fective control depends on developing an integrated pest
management program that is best suited for the individ-
ual client. Understanding sources of re-infestation is an
integral part of this program. Fleas begin feeding as soon
as they infest a host. A blood meal is required for egg
production, which starts approximately 36 hours after
feeding [26, 27]. Each flea may feed several times a day
and may remain on the host for up to 21 days [26]. Dur-
ing this time, they produce many eggs that fall off the
host and develop in the environment. Therefore, the ma-
jority of adult flea infestations are acquired as new infes-
tations from the environment [27] and optimal control
programs must be focused on eliminating the adult
stages before they start laying eggs and seeding the en-
vironment. Quickly removing adult fleas infesting the
dog is the first step in a successful flea control program.
This can be achieved by using a product like advantus™
soft chewable tablets that are characterized by a fast on-
set of activity (start-to-kill) and a fast speed of kill. Oral
imidacloprid treatment with advantus™ soft chewable
tablets will eliminate flea infestations on the dog within
4 hours of treatment and prevent contamination of the
environment with flea eggs.
Flea Allergy Dermatitis (FAD) is caused by flea bites in
susceptible dogs and the feeding activity of one flea can
initiate this reaction. In heavy infestations acute FAD
can be an extremely debilitating and painful experience
for the dog. Use of advantus™ soft chewable tablets ad-
ministered to dogs with flea burdens will start to provide
relief from biting fleas in one hour.
Fleas transmit several diseases to pets, through flea
bites, flea feces or when fleas are ingested during groom-
ing [3]. These diseases include, but are not limited to,
bartonellosis (Bartonella henselae) and mycoplasmosis
(Mycoplasma haemofelis). Fleas are also an intermediate
hosts for Dipylidium caninum [28]. Quick removal of
adult fleas using advantus™ soft chewable tablets (fast
start-to-kill and a fast speed of kill) may aid in prevent-
ing flea-transmitted diseases in dogs.
A wide margin of safety of advantus™ soft chewable
tablets was demonstrated with daily administration for
6 months at approximately 1, 3 and 5 times the recom-
mend dose. No adverse events were reported which sup-
ports the extended daily use of the soft chewable tablets
for dogs. Daily use of the soft chewable tablet will elim-
inate flea infestations on the dog before they start laying
eggs. The presence of dogs in an infested environment
will provide constant stimulation for the pre-adult stages
of the fleas to emerge and infest the dog, but newly
infesting fleas will be eliminated quickly by treatment of
the dog with advantus™ soft chewable tablets. Studieshave shown that in heavily contaminated environments
it takes up to 2 months (60 days) to clean the environ-
ments of cycling flea populations [29].
Conclusion
Development of advantus™ soft chewable tablets for the
treatment of adult flea infestations of dogs was de-
scribed. The characteristics of the product include con-
venience of administering imidacloprid as a soft
chewable tablet that is rapidly absorbed within approxi-
mately 1 hour and eliminated rapidly as well, with a
half-life of approximately 2 hours. These characteristics
translate to rapid start to kill activity of 1 hour and
speed of flea kill at 4 hours. Substantial evidence of effi-
cacy was demonstrated with 96 % efficacy as early as
4 hours. The safety profile was excellent with no test
substance related adverse events reported following 1, 3
and 5 times the dose administered daily for 6 months.
Excellent safety and substantial efficacy was also demon-
strated in a field efficacy study in client owned dogs.
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